We are live on ! Find out more
ODT

Odonate Therapeutics, Inc. Common Stock

Delisted

ODT was delisted on the 14th of January, 2022.

82 hedge funds and large institutions have $818M invested in Odonate Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 43 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 14

67% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 9

6% more funds holding

Funds holding: 7782 (+5)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

28% less capital invested

Capital invested by funds: $1.14B → $818M (-$322M)

Holders
82
Holders Change
+5
Holders Change %
+6.49%
% of All Funds
1.8%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.11%
New
15
Increased
43
Reduced
14
Closed
9
Calls
Puts
Net Calls
Net Calls Change

ODT Hedge Fund Activity: Q3 2019 in Review

82 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q3 2019, worth a combined $818M — down 28% from $1.14B a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new ODT positions and 9 closed out — a net gain of 6 holders — while 43 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $9.61M. The largest seller was Franklin Resources, cutting an estimated $7.98M.

  • 82 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q3 2019, up from 77 in Q2 2019.
  • Funds reported $818M of Odonate Therapeutics, Inc. Common Stock stock for Q3 2019, down 28% quarter-over-quarter.
  • 15 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q3 2019 and 9 closed out, a net change of +6 holders.
  • The largest Odonate Therapeutics, Inc. Common Stock buyer in Q3 2019 was BlackRock, an estimated $9.61M added.
  • The largest Odonate Therapeutics, Inc. Common Stock seller in Q3 2019 was Franklin Resources, an estimated $7.98M sold.

Based on aggregated 13F filings for Q3 2019.